Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia

Anthony Monteforte, Brian Lam, Michael Sherman, Kayla Henderson, Andrew D. Sligar, Adrianne Spencer, Brian Tang, Andrew K. Dunn, Aaron B. Baker

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Peripheral ischemia as a result of occlusive vascular disease is a widespread problem in patients older than the age of 65. Angiogenic therapies that can induce microvascular growth have great potential for providing a long-lasting solution for patients with ischemia and would provide an appealing alternative to surgical and percutaneous interventions. However, many angiogenic therapies have seen poor efficacy in clinical trials, suggesting that patients with long-term peripheral ischemia have considerable therapeutic resistance to angiogenic stimuli. Glioblastoma is one of the most angiogenic tumor types, inducing robust vessel growth in the area surrounding the tumor. One major angiogenic mechanism used by the tumor cells to induce blood vessel growth is the production of exosomes and other extracellular vesicles that can carry pro-angiogenic and immunomodulatory signals. Here, we explored whether the pro-angiogenic aspects of glioblastoma-derived exosomes could be harnessed to promote angiogenesis and healing in the context of peripheral ischemic disease. We demonstrate that the exosomes derived from glioblastoma markedly enhance endothelial cell proliferation and increase endothelial tubule formation in vitro. An analysis of the microRNA expression using next generation sequencing identified that exosomes contained a high concentration of miR-221. In addition, we found that glioblastoma exosomes contained significant amounts of the proteoglycans glypican-1 and syndecan-4, which can serve as co-receptors for angiogenic factors, including fibroblast growth factor-2 (FGF-2). In a hindlimb ischemia model in mice, we found that the exosomes promoted enhanced revascularization in comparison to control alginate gels and FGF-2 treatment alone. Taken together, our results support the fact that glioblastoma-derived exosomes have powerful effects in increasing revascularization in the context of peripheral ischemia.

Original languageEnglish (US)
Pages (from-to)1251-1261
Number of pages11
JournalTissue Engineering - Part A
Volume23
Issue number21-22
DOIs
StatePublished - Nov 1 2017

Fingerprint

Exosomes
Glioblastoma
Tumors
Ischemia
Fibroblast Growth Factor 2
Fibroblasts
Syndecan-4
Glypicans
Angiogenesis Inducing Agents
Alginate
Endothelial cells
Blood vessels
Cell proliferation
Proteoglycans
MicroRNAs
Therapeutics
Gels
Cells
Growth
Neoplasms

Keywords

  • exosomes
  • glioblastoma
  • ischemia
  • miR-221
  • therapeutic angiogenesis

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomaterials
  • Biomedical Engineering

Cite this

Monteforte, A., Lam, B., Sherman, M., Henderson, K., Sligar, A. D., Spencer, A., ... Baker, A. B. (2017). Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia. Tissue Engineering - Part A, 23(21-22), 1251-1261. https://doi.org/10.1089/ten.tea.2016.0508

Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia. / Monteforte, Anthony; Lam, Brian; Sherman, Michael; Henderson, Kayla; Sligar, Andrew D.; Spencer, Adrianne; Tang, Brian; Dunn, Andrew K.; Baker, Aaron B.

In: Tissue Engineering - Part A, Vol. 23, No. 21-22, 01.11.2017, p. 1251-1261.

Research output: Contribution to journalArticle

Monteforte, A, Lam, B, Sherman, M, Henderson, K, Sligar, AD, Spencer, A, Tang, B, Dunn, AK & Baker, AB 2017, 'Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia', Tissue Engineering - Part A, vol. 23, no. 21-22, pp. 1251-1261. https://doi.org/10.1089/ten.tea.2016.0508
Monteforte, Anthony ; Lam, Brian ; Sherman, Michael ; Henderson, Kayla ; Sligar, Andrew D. ; Spencer, Adrianne ; Tang, Brian ; Dunn, Andrew K. ; Baker, Aaron B. / Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia. In: Tissue Engineering - Part A. 2017 ; Vol. 23, No. 21-22. pp. 1251-1261.
@article{1daff153b1cf4c1ab4a7bcb918b6b409,
title = "Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia",
abstract = "Peripheral ischemia as a result of occlusive vascular disease is a widespread problem in patients older than the age of 65. Angiogenic therapies that can induce microvascular growth have great potential for providing a long-lasting solution for patients with ischemia and would provide an appealing alternative to surgical and percutaneous interventions. However, many angiogenic therapies have seen poor efficacy in clinical trials, suggesting that patients with long-term peripheral ischemia have considerable therapeutic resistance to angiogenic stimuli. Glioblastoma is one of the most angiogenic tumor types, inducing robust vessel growth in the area surrounding the tumor. One major angiogenic mechanism used by the tumor cells to induce blood vessel growth is the production of exosomes and other extracellular vesicles that can carry pro-angiogenic and immunomodulatory signals. Here, we explored whether the pro-angiogenic aspects of glioblastoma-derived exosomes could be harnessed to promote angiogenesis and healing in the context of peripheral ischemic disease. We demonstrate that the exosomes derived from glioblastoma markedly enhance endothelial cell proliferation and increase endothelial tubule formation in vitro. An analysis of the microRNA expression using next generation sequencing identified that exosomes contained a high concentration of miR-221. In addition, we found that glioblastoma exosomes contained significant amounts of the proteoglycans glypican-1 and syndecan-4, which can serve as co-receptors for angiogenic factors, including fibroblast growth factor-2 (FGF-2). In a hindlimb ischemia model in mice, we found that the exosomes promoted enhanced revascularization in comparison to control alginate gels and FGF-2 treatment alone. Taken together, our results support the fact that glioblastoma-derived exosomes have powerful effects in increasing revascularization in the context of peripheral ischemia.",
keywords = "exosomes, glioblastoma, ischemia, miR-221, therapeutic angiogenesis",
author = "Anthony Monteforte and Brian Lam and Michael Sherman and Kayla Henderson and Sligar, {Andrew D.} and Adrianne Spencer and Brian Tang and Dunn, {Andrew K.} and Baker, {Aaron B.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1089/ten.tea.2016.0508",
language = "English (US)",
volume = "23",
pages = "1251--1261",
journal = "Tissue Engineering - Part A.",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "21-22",

}

TY - JOUR

T1 - Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia

AU - Monteforte, Anthony

AU - Lam, Brian

AU - Sherman, Michael

AU - Henderson, Kayla

AU - Sligar, Andrew D.

AU - Spencer, Adrianne

AU - Tang, Brian

AU - Dunn, Andrew K.

AU - Baker, Aaron B.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Peripheral ischemia as a result of occlusive vascular disease is a widespread problem in patients older than the age of 65. Angiogenic therapies that can induce microvascular growth have great potential for providing a long-lasting solution for patients with ischemia and would provide an appealing alternative to surgical and percutaneous interventions. However, many angiogenic therapies have seen poor efficacy in clinical trials, suggesting that patients with long-term peripheral ischemia have considerable therapeutic resistance to angiogenic stimuli. Glioblastoma is one of the most angiogenic tumor types, inducing robust vessel growth in the area surrounding the tumor. One major angiogenic mechanism used by the tumor cells to induce blood vessel growth is the production of exosomes and other extracellular vesicles that can carry pro-angiogenic and immunomodulatory signals. Here, we explored whether the pro-angiogenic aspects of glioblastoma-derived exosomes could be harnessed to promote angiogenesis and healing in the context of peripheral ischemic disease. We demonstrate that the exosomes derived from glioblastoma markedly enhance endothelial cell proliferation and increase endothelial tubule formation in vitro. An analysis of the microRNA expression using next generation sequencing identified that exosomes contained a high concentration of miR-221. In addition, we found that glioblastoma exosomes contained significant amounts of the proteoglycans glypican-1 and syndecan-4, which can serve as co-receptors for angiogenic factors, including fibroblast growth factor-2 (FGF-2). In a hindlimb ischemia model in mice, we found that the exosomes promoted enhanced revascularization in comparison to control alginate gels and FGF-2 treatment alone. Taken together, our results support the fact that glioblastoma-derived exosomes have powerful effects in increasing revascularization in the context of peripheral ischemia.

AB - Peripheral ischemia as a result of occlusive vascular disease is a widespread problem in patients older than the age of 65. Angiogenic therapies that can induce microvascular growth have great potential for providing a long-lasting solution for patients with ischemia and would provide an appealing alternative to surgical and percutaneous interventions. However, many angiogenic therapies have seen poor efficacy in clinical trials, suggesting that patients with long-term peripheral ischemia have considerable therapeutic resistance to angiogenic stimuli. Glioblastoma is one of the most angiogenic tumor types, inducing robust vessel growth in the area surrounding the tumor. One major angiogenic mechanism used by the tumor cells to induce blood vessel growth is the production of exosomes and other extracellular vesicles that can carry pro-angiogenic and immunomodulatory signals. Here, we explored whether the pro-angiogenic aspects of glioblastoma-derived exosomes could be harnessed to promote angiogenesis and healing in the context of peripheral ischemic disease. We demonstrate that the exosomes derived from glioblastoma markedly enhance endothelial cell proliferation and increase endothelial tubule formation in vitro. An analysis of the microRNA expression using next generation sequencing identified that exosomes contained a high concentration of miR-221. In addition, we found that glioblastoma exosomes contained significant amounts of the proteoglycans glypican-1 and syndecan-4, which can serve as co-receptors for angiogenic factors, including fibroblast growth factor-2 (FGF-2). In a hindlimb ischemia model in mice, we found that the exosomes promoted enhanced revascularization in comparison to control alginate gels and FGF-2 treatment alone. Taken together, our results support the fact that glioblastoma-derived exosomes have powerful effects in increasing revascularization in the context of peripheral ischemia.

KW - exosomes

KW - glioblastoma

KW - ischemia

KW - miR-221

KW - therapeutic angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=85033781485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033781485&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2016.0508

DO - 10.1089/ten.tea.2016.0508

M3 - Article

VL - 23

SP - 1251

EP - 1261

JO - Tissue Engineering - Part A.

JF - Tissue Engineering - Part A.

SN - 1937-3341

IS - 21-22

ER -